
order to have their arthritic pain relieved without other side-effects The blockbuster anti-athritis drug Vioxx doubled the risk of heart attacks and was not fit to be on the market for arthritis pain, a federal...

companies like Merck from hucksters of ¡°patent medicines.¡± The scandal at Merck about the arthritis drug Vioxx came after his time

in the clear after they stopped taking the now banned painkiller rofecoxib (Vioxx) might have to think again. The risks of the drug, which was pulled off the market in 2004 after it was linked to heart attacks and...

was due to the same type of blood-clot risk that had sparked the withdrawal of Merck's arthritis drug Vioxx, although no such risk has been reported from the medicine's clinical trial data. "A rejection...

to "hunt" through patient records for potential candidates for their blockbuster anti-arthritis drug Vioxx. The Federal Court was told the company aimed to identify 100 patients of each targeted general practitione...

THE international pharmaceutical giant behind anti-arthritis drug Vioxx maintains there is not enough scientific proof to link the drug to heart attacks, despite the company withdrawing it from the market almost...

600 other litigants in a lawsuit against U.S. pharmaceutical firm Merck & Co. over its since-recalled drug Vioxx. The painkiller was taken off the global market in 2004 after research showed it raised the risk of...

The Federal Court has ruled the makers of the controversial arthritis drug Vioxx put a defective drug on the market, which doubled the risk of heart attacks. Melbourne man Graeme Peterson has been awarded compensati...

safety of Vioxx." Dr Dickman said his "clear impression" at the time was that Vioxx and its rival drug Celebrex were the safest drugs on the market and it would have been "almost negligent"...

I wrote yesterday on the reasons why the anti-arthritis drug Vioxx has been withdrawn from sale: People taking it have a small (in absolute terms) extra risk of having a non-fatal heart attack. A medical corresponde...